Matches in SemOpenAlex for { <https://semopenalex.org/work/W2170374219> ?p ?o ?g. }
- W2170374219 abstract "Background Anti‐leukotrienes (5‐lipoxygenase inhibitors and leukotriene receptors antagonists) serve as alternative monotherapy to inhaled corticosteroids (ICS) in the management of recurrent and/or chronic asthma in adults and children. Objectives To determine the safety and efficacy of anti‐leukotrienes compared to inhaled corticosteroids as monotherapy in adults and children with asthma and to provide better insight into the influence of patient and treatment characteristics on the magnitude of effects. Search methods We searched MEDLINE (1966 to Dec 2010), EMBASE (1980 to Dec 2010), CINAHL (1982 to Dec 2010), the Cochrane Airways Group trials register, and the Cochrane Central Register of Controlled Trials (Dec 2010), abstract books, and reference lists of review articles and trials. We contacted colleagues and the international headquarters of anti‐leukotrienes producers. Selection criteria We included randomised trials that compared anti‐leukotrienes with inhaled corticosteroids as monotherapy for a minimum period of four weeks in patients with asthma aged two years and older. Data collection and analysis Two review authors independently assessed the methodological quality of trials and extracted data. The primary outcome was the number of patients with at least one exacerbation requiring systemic corticosteroids. Secondary outcomes included patients with at least one exacerbation requiring hospital admission, lung function tests, indices of chronic asthma control, adverse effects, withdrawal rates and biological inflammatory markers. Main results Sixty‐five trials met the inclusion criteria for this review. Fifty‐six trials (19 paediatric trials) contributed data (representing total of 10,005 adults and 3,333 children); 21 trials were of high methodological quality; 44 were published in full‐text. All trials pertained to patients with mild or moderate persistent asthma. Trial durations varied from four to 52 weeks. The median dose of inhaled corticosteroids was quite homogeneous at 200 µg/day of microfine hydrofluoroalkane‐propelled beclomethasone or equivalent (HFA‐BDP eq). Patients treated with anti‐leukotrienes were more likely to suffer an exacerbation requiring systemic corticosteroids (N = 6077 participants; risk ratio (RR) 1.51, 95% confidence interval (CI) 1.17, 1.96). For every 28 (95% CI 15 to 82) patients treated with anti‐leukotrienes instead of inhaled corticosteroids, there was one additional patient with an exacerbation requiring rescue systemic corticosteroids. The magnitude of effect was significantly greater in patients with moderate compared with those with mild airway obstruction (RR 2.03, 95% CI 1.41, 2.91 versus RR 1.25, 95% CI 0.97, 1.61), but was not significantly influenced by age group (children representing 23% of the weight versus adults), anti‐leukotriene used, duration of intervention, methodological quality, and funding source. Significant group differences favouring inhaled corticosteroids were noted in most secondary outcomes including patients with at least one exacerbation requiring hospital admission (N = 2715 participants; RR 3.33; 95% CI 1.02 to 10.94), the change from baseline FEV1 (N = 7128 participants; mean group difference (MD) 110 mL, 95% CI 140 to 80) as well as other lung function parameters, asthma symptoms, nocturnal awakenings, rescue medication use, symptom‐free days, the quality of life, parents' and physicians' satisfaction. Anti‐leukotriene therapy was associated with increased risk of withdrawals due to poor asthma control (N = 7669 participants; RR 2.56; 95% CI 2.01 to 3.27). For every thirty one (95% CI 22 to 47) patients treated with anti‐leukotrienes instead of inhaled corticosteroids, there was one additional withdrawal due to poor control. Risk of side effects was not significantly different between both groups. Authors' conclusions As monotherapy, inhaled corticosteroids display superior efficacy to anti‐leukotrienes in adults and children with persistent asthma; the superiority is particularly marked in patients with moderate airway obstruction. On the basis of efficacy, the results support the current guidelines' recommendation that inhaled corticosteroids remain the preferred monotherapy." @default.
- W2170374219 created "2016-06-24" @default.
- W2170374219 creator A5034261245 @default.
- W2170374219 creator A5065533338 @default.
- W2170374219 date "2012-05-16" @default.
- W2170374219 modified "2023-10-01" @default.
- W2170374219 title "Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children" @default.
- W2170374219 cites W147317284 @default.
- W2170374219 cites W1490794304 @default.
- W2170374219 cites W1536632456 @default.
- W2170374219 cites W1595184853 @default.
- W2170374219 cites W1598602811 @default.
- W2170374219 cites W162470771 @default.
- W2170374219 cites W1909409123 @default.
- W2170374219 cites W1963557400 @default.
- W2170374219 cites W1963568662 @default.
- W2170374219 cites W1963602564 @default.
- W2170374219 cites W1964042032 @default.
- W2170374219 cites W1964078967 @default.
- W2170374219 cites W1964105299 @default.
- W2170374219 cites W1964559015 @default.
- W2170374219 cites W1965491374 @default.
- W2170374219 cites W1965720965 @default.
- W2170374219 cites W1965778637 @default.
- W2170374219 cites W1965794676 @default.
- W2170374219 cites W1965858343 @default.
- W2170374219 cites W1966146541 @default.
- W2170374219 cites W1966615063 @default.
- W2170374219 cites W1967555231 @default.
- W2170374219 cites W1968660451 @default.
- W2170374219 cites W1968660637 @default.
- W2170374219 cites W1969545770 @default.
- W2170374219 cites W1971093510 @default.
- W2170374219 cites W1971145825 @default.
- W2170374219 cites W1972129219 @default.
- W2170374219 cites W1972351481 @default.
- W2170374219 cites W1972720055 @default.
- W2170374219 cites W1972810336 @default.
- W2170374219 cites W1974121972 @default.
- W2170374219 cites W1974257761 @default.
- W2170374219 cites W1975106806 @default.
- W2170374219 cites W1975162102 @default.
- W2170374219 cites W1975272363 @default.
- W2170374219 cites W1975315932 @default.
- W2170374219 cites W1975914622 @default.
- W2170374219 cites W1976011139 @default.
- W2170374219 cites W1978672259 @default.
- W2170374219 cites W1979096132 @default.
- W2170374219 cites W1979159965 @default.
- W2170374219 cites W1979192746 @default.
- W2170374219 cites W1979358858 @default.
- W2170374219 cites W1980298378 @default.
- W2170374219 cites W1980467751 @default.
- W2170374219 cites W1980574092 @default.
- W2170374219 cites W1981468497 @default.
- W2170374219 cites W1981856188 @default.
- W2170374219 cites W1981916494 @default.
- W2170374219 cites W1982116706 @default.
- W2170374219 cites W1982269964 @default.
- W2170374219 cites W1985134155 @default.
- W2170374219 cites W1985400158 @default.
- W2170374219 cites W1986235865 @default.
- W2170374219 cites W1986555896 @default.
- W2170374219 cites W1986733730 @default.
- W2170374219 cites W1987343787 @default.
- W2170374219 cites W1987622884 @default.
- W2170374219 cites W1988494947 @default.
- W2170374219 cites W1988895307 @default.
- W2170374219 cites W1989350620 @default.
- W2170374219 cites W1990863296 @default.
- W2170374219 cites W1991819079 @default.
- W2170374219 cites W1991857563 @default.
- W2170374219 cites W1992733705 @default.
- W2170374219 cites W1993821373 @default.
- W2170374219 cites W1995100515 @default.
- W2170374219 cites W1995918693 @default.
- W2170374219 cites W1996134359 @default.
- W2170374219 cites W1996982788 @default.
- W2170374219 cites W1997712398 @default.
- W2170374219 cites W1997889822 @default.
- W2170374219 cites W199806695 @default.
- W2170374219 cites W1998903070 @default.
- W2170374219 cites W2000674431 @default.
- W2170374219 cites W2000861709 @default.
- W2170374219 cites W2002162310 @default.
- W2170374219 cites W2002677103 @default.
- W2170374219 cites W2002752649 @default.
- W2170374219 cites W2003190574 @default.
- W2170374219 cites W2004829045 @default.
- W2170374219 cites W2004995337 @default.
- W2170374219 cites W2005465488 @default.
- W2170374219 cites W2006414917 @default.
- W2170374219 cites W2007567016 @default.
- W2170374219 cites W2008188018 @default.
- W2170374219 cites W2008620220 @default.
- W2170374219 cites W2008660872 @default.
- W2170374219 cites W2008775809 @default.
- W2170374219 cites W2009807650 @default.
- W2170374219 cites W2011487006 @default.
- W2170374219 cites W2011818405 @default.